SAN FRANCISCO, Sept. 11, 2019 /PRNewswire/ -- The global
interleukin inhibitors market size is expected to reach
USD 74.6 billion by 2026,
according to a new report by Grand View Research, Inc., exhibiting
a CAGR of 17.4% over the forecast period. This can be
attributed to a strong pipeline with upcoming launches of
late-stage pipeline drugs.
Key suggestions from the report:
- Psoriatic arthritis and IBD are projected to register
fastest growth through to 2026
- IL-17 is likely to overtake IL-23 as the leading type by
2026
- IL-5 inhibitors for asthma to witness strong growth in the
near future
- Asia Pacific is expected to
exhibit the fastest regional growth
- Despite the high price of IL-inhibitors, favorable
reimbursement policies are likely to provide affordability and
support market penetration
Read 103 page research report with TOC on "Interleukin
Inhibitors Market Size, Share & Trend Analysis Report By
Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis,
Asthma, IBD), By Type (IL-17, IL-23), And Segment Forecasts, 2019 -
2026" at:
https://www.grandviewresearch.com/industry-analysis/interleukin-inhibitors-market
The therapeutic landscape in this market is becoming
increasingly competitive, as drugs are compared in head-to-head
trials to determine superiority in terms of safety, efficacy, and
tolerance. For instance, UCB's bimekizumab is currently under
investigation in three such trials against Humira (trial name: BE
SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for
plaque psoriasis.
Furthermore, increasing investments on various clinical trials
and strategic alliances between pharmaceutical companies and
research organizations for development of novel molecules are few
major contributors to interleukin inhibitors market growth. For
instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated
with Massachusetts General Hospital for developing Actemra
(tocilizumab) for the treatment of giant cell arteritis.
Rise in consumer awareness about various autoimmune diseases and
their treatment options is anticipated to impel demand. For
instance, Arthritis Ireland launched an awareness campaign for
rheumatoid arthritis, educating the public about different
treatment options and significance of early diagnosis. In addition,
the European Federation of Crohn's & Ulcerative Colitis
Association offers various initiatives to create awareness among
patients suffering from Inflammatory Bowel Disease (IBD).
Grand View Research has segmented the global interleukin
inhibitors market based on application, type, and region:
- Interleukin Inhibitors Application Outlook (Revenue, USD
Million, 2014 - 2026)
-
- Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Asthma
- Inflammatory Bowel Disease
- Others
- Interleukin Inhibitors Type Outlook (Revenue, USD Million,
2014 - 2026)
-
- IL-1
- IL-5
- IL-6
- IL-17
- IL-23
- Others
- Interleukin Inhibitors Regional Outlook (Revenue, USD
Million, 2014 - 2026)
-
- North America
-
- Europe
-
- UK
- Germany
- France
- Italy
- Spain
- Asia Pacific
-
- Japan
- China
- India
- South Korea
- Australia
- Latin America
-
- Middle East & Africa
-
- South Africa
- UAE
- Saudi Arabia
Find more research reports on Pharmaceuticals
Industry, by Grand View Research:
- Prenatal and New-born Genetic Testing
Market – Increasing prevalence of genetic diseases
such as Down syndrome, Edward syndrome and Patau syndrome in new
born and prenatal is the high impact rendering driver for the
growth of prenatal and new-born genetic testing market.
- Scleroderma Diagnostics And Therapeutics
Market – Increasing prevalence of
scleroderma and rising incidences of genetic mutations coupled with
drastic changes in environment is the high impact rendering divers
for scleroderma diagnostics and therapeutics market.
- Anti-inflammatory Peptides Market –
Anti-inflammatory peptides market is expected to grow over the
forecast period owing to the increasing incidences of diseases such
as autoimmune diseases, inflammatory bowel disease, multiple
sclerosis, and psoriasis.
Gain access to Grand View Compass, our BI
enabled intuitive market research database of 10,000+
reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting
company, provides syndicated as well as customized research reports
and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425
analysts and consultants, adding more than 1200 market research
reports to its vast database each year. These reports offer
in-depth analysis on 46 industries across 25 major countries
worldwide. With the help of an interactive market intelligence
platform, Grand View Research helps Fortune 500 companies and
renowned academic institutes understand the global and regional
business environment and gauge the opportunities that lie
ahead.
Contact:
Sherry
James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter